About 23,993 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  8,717 results

Therapeutic targeting of the inflammasome in myeloid malignancies.
https://doi.org/10.1038/s41408-021-00547-8 10.1038/sj.onc.1210757 10.1002/ajh.20993 10.1182/blood-2012-01-404699 10.1056/NEJMoa1409405 10.1038/nm0797-730 10.1002/ajh.23908 10.1200/JCO.2014.60.0890 10.1182/blood.V99.12.4326 10.1016/S0145-2126(01)00193-X 10.1016/S0145-2126(96)00008-2 10.1182/blood-2008-02-139824 10.1158/0008-5472.CAN-10-2933 10.1182/blood-2015-01-621631 10.1111/j.1600-0609.2005.00551.x 10.1158/1078-0432.CCR-06-2108 10.1016/j.yexmp.2010.01.009 10.1182/blood-2016-07-730556 10.1182/blood-2018-10-844654 10.1182/blood-2016-03-643544 10.1111/j.1365-2141.1993.tb03157.x 10.1016/S0145-2126(02)00095-4 10.1016/j.immuni.2006.04.008 10.1016/j.jmb.2006.09.054 10.3389/fimmu.2016.00390 10.1038/leu.2013.180 10.1016/j.ccr.2013.05.006 10.1126/scitranslmed.aaw8828 10.1038/s41556-019-0314-5 10.1182/blood-2018-03-784116 10.3389/fgene.2014.00219 10.1016/j.celrep.2014.07.062 10.1038/s41590-020-0663-z 10.1177/2040620720958586 10.3389/fonc.2020.584766 10.1084/jem.20180147 10.3389/fonc.2016.00151 10.1172/JCI67580 10.3324/haematol.2016.158857 10.1182/blood-2017-05-782912 10.1016/j.ccell.2016.06.002 10.3892/ol.2017.6562 10.1007/s00011-016-1012-4 10.1038/s41467-020-15497-1 10.1242/dev.012385 10.1182/blood-2010-12-325357 10.3389/fimmu.2013.00426 10.1101/gad.13.11.1398 10.1182/blood.V95.8.2543 10.1038/nature18320 10.1016/S1097-2765(00)80312-3 10.1016/S0092-8674(00)80076-8 10.1073/pnas.92.15.7075 10.1016/j.immuni.2019.05.005 10.1016/j.stem.2019.05.019 10.1016/j.cell.2014.10.031 10.1038/nature15252 10.1084/jem.20131141 10.1016/j.ccell.2018.07.003 10.1038/nm.2054 10.3324/haematol.2012.066613 10.1182/blood-2018-99-116199 10.1182/blood-2017-06-789800 10.1182/blood-2018-99-112891 10.1182/blood-2020-136398 10.1182/blood.V128.22.227.227 10.1002/ajh.24746 10.1021/acsmedchemlett.0c00255 10.1182/bloodadvances.2019000757 10.1186/ar3297 10.1016/j.blre.2017.05.001 10.1038/nm.3806 10.1038/s41598-018-26775-w 10.3389/fimmu.2019.02538 10.15252/emmm.201708689 10.1073/pnas.1716095115 10.1016/j.clml.2019.05.008 10.1124/jpet.106.111344 10.1038/nature18629
Blood Cancer Journal; Chakraborty S, Shapiro LC et. al.

Sep 16th, 2021 - Even though genetic perturbations and mutations are important for the development of myeloid malignancies, the effects of an inflammatory microenvironment are a critical modulator of carcinogenesis. Activation of the innate immune system through v...

Patient-reported outcomes predict overall survival in older patients with acute myeloid...
Journal of Geriatric Oncology; Peipert JD, Efficace F et. al.

Sep 16th, 2021 - Patient-reported outcomes (PROs) predict overall survival (OS) in many cancer types, but there is little evidence of their prognostic value in older patients with acute myeloid leukemia (AML). We examined whether the Functional Assessment of Cance...

The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility t...
https://doi.org/10.1038/s41467-021-25664-7 10.1056/NEJMoa1301689 10.1016/S0268-960X(03)00040-7 10.1182/blood-2011-03-343988 10.1182/blood-2009-07-235358 10.1074/jbc.M808222200 10.1016/j.cell.2006.06.041 10.1158/0008-5472.CAN-07-0045 10.1016/j.ccell.2015.02.006 10.1371/journal.pgen.1003007 10.1016/j.celrep.2018.08.057 10.1182/blood-2007-10-115873 10.1182/blood.V94.2.417 10.1200/JCO.2005.16.600 10.7554/eLife.13941 10.1016/S0092-8674(00)80216-0 10.1016/j.hbpd.2019.08.006 10.1016/j.celrep.2016.02.045 10.1080/10428194.2018.1509314 10.1038/sj.onc.1207108 10.1038/nature04980 10.1371/journal.pone.0001609 10.18632/oncotarget.20288 10.1038/sj.cdd.4402139 10.12659/MSM.911904 10.1101/gad.1035902 10.1007/s00018-012-1256-2 10.1016/S0165-4608(03)00102-X 10.1091/mbc.e07-06-0601 10.1073/pnas.1008937107 10.1074/jbc.M114.610196 10.1038/onc.2011.32 10.18632/oncotarget.26877 10.1016/j.ctrv.2017.10.007 10.1182/blood-2004-05-1693 10.1038/s41467-018-04647-1 10.1038/s41467-019-09525-y 10.1152/physrev.00012.2016 10.1093/nar/gku383 10.1038/nmeth.2847 10.1038/nmeth.2557 10.1073/pnas.1608644113 10.1038/nbt.1511 10.1101/gr.1239303 10.1016/j.celrep.2016.09.079 10.1093/bioinformatics/bts635 10.1093/bioinformatics/btt656 10.1186/gb-2010-11-3-r25 10.1371/journal.pone.0157022 10.1016/j.cell.2017.10.049
Nature Communications; Khateb A, Deshpande A et. al.

Sep 15th, 2021 - Acute myeloid leukemia (AML) remains incurable, largely due to its resistance to conventional treatments. Here, we find that increased abundance of the ubiquitin ligase RNF5 contributes to AML development and survival. High RNF5 expression in AML ...

see more →

Guidelines  10 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Acute myeloid leukemia, version 2.2013.
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

Myelodysplastic syndromes: clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

see more →

Drugs  28 results see all →

Clinicaltrials.gov  22 results

New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Aug 31st, 2021 - This study is to investigate the therapeutic efficacy and side effect of chidamide, azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid leukemia

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Aug 27th, 2021 - This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remissi...

Hetrombopag Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia

Aug 27th, 2021 - Myelodysplastic syndrome (MDS) is a kind of clonal myeloid tumor. The major manifestation is decrease of tri-lineages of blood due to ineffective and abnormal hematopoiesis, some of which can progress to acute myeloid leukemia. According to the in...

Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Aug 26th, 2021 - The patients will receive infusion of anti-FLT3 CAR T-cells targeting FLT3 to evaluate the safety and efficacy of anti-FLT3 CAR T-Cells in relapsed or refractory acute myeloid leukemia.

A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloi...

Aug 25th, 2021 - This will be a multi-center, international, double-blind, placebo-controlled study in previously untreated participants with acute myeloid leukemia (AML) harboring nucleophosmin-1 (NPM1) mutations. Upon fulfillment of all eligibility criteria, par...

see more →

News  819 results

Dr. Richardson on the Toxicity Profile of Melphalan Flufenamide in Multiple Myeloma

Aug 17th, 2021 - Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center, institute physician at Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, dis...

Dr. Roboz on the Importance of Genomic Analysis in AML

Aug 2nd, 2021 - Gail J. Roboz, MD, professor of medicine, director of the Clinical and Translational Leukemia Program, Weill Medical College, Cornell University, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients ...

Ficlatuzumab Plus Chemo Shows Early Promise in Refractory AML

Jul 21st, 2021 - NEW YORK (Reuters Health) - The combination of ficlatuzumab plus chemotherapy showed considerable early promise in relapsed/refractory acute myeloid leukemia (AML) in a small phase-1 study. "The high rate of complete remissions was surprising to u...

Eprenetapopt/Azacitidine Combo Elicits Promising Activity in TP53-Mutant MDS and AML

Jul 13th, 2021 - The combination of eprenetapopt (APR-246) and azacitidine demonstrated a promising safety profile as well as encouraging clinical activity in a high-risk population of patients with TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leu...

Targeting CLL1-Positive Cells Shows Efficacy in Early Trial in Pediatric AML

Jul 9th, 2021 - Investigators validated the safety and efficacy of anti-C-type lectin-like molecule-1 (CLL-1)-based CAR T cells in a small clinical trial of pediatric patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), according to findings pres...

see more →

Patient Education  1 results see all →